Extended Data Fig. 2: Pharmacokinetic concentration-time profiles by ADA positive and negative (pharmacokinetic set). | Nature Medicine

Extended Data Fig. 2: Pharmacokinetic concentration-time profiles by ADA positive and negative (pharmacokinetic set).

From: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial

Extended Data Fig. 2: Pharmacokinetic concentration-time profiles by ADA positive and negative (pharmacokinetic set).The alternative text for this image may have been generated using AI.

The siltartoxatug serum concentration-time profiles was presented by ADA-positive (n = 58) and ADA-negative (n = 378) participants, with y-axis plotted using a linear scale (a) and a logarithmic scale (b). Participants included in the analysis were those who received siltartoxatug and had at least 1 available post-administration data for pharmacokinetics. Data are presented as arithmetic mean ± arithmetic standard deviation. The dashed line indicates the lower limit of quantification for the bioanalytical method for measuring the siltartoxatug concentration (20 ng/mL).

Back to article page